查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466461

放射性药物市场：按类型、手术数量和应用分类 - 2024-2030 年全球预测

Radiopharmaceuticals Market by Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine), Procedural Volume (Diagnostic Procedures, Therapeutic Procedures), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

放射性药物市场规模预计2023年为51.5亿美元，2024年达到54.8亿美元，预计2030年将达到80亿美元，复合年增长率为6.47%。

放射性药物是一类独特的含有放射性同位素的药物製剂，用于核医领域。这些化合物具有发射辐射的能力，可用于多种用途，包括诊断、治疗和研究。放射性药物在疾病检测和治疗、增加早期诊断、监测疾病进展和提高治疗性介入的有效性方面具有重要价值。由于癌症和心血管疾病等需要先进诊断技术的慢性疾病盛行率不断上升，放射性药物的普及正在显着增加。 PET 和 SPECT 等成像技术的进步也推动了放射性药物市场的成长。此外，个人化医疗和标靶治疗方法的日益采用也推动了对治疗应用的放射性同位素的需求。儘管预计将出现可观的成长，但放射性药物市场面临挑战，例如严格的监管要求，导致新放射性药物的核准非常耗时。开发和製造放射性药物的高昂成本以及对专业设施和训练有素的人员的需求增加了该行业面临的挑战。然而，不断增加的研发投资为放射性药物市场的创新和扩展提供了充足的机会。此外，将诊断和治疗功能结合到单一药物中的治疗诊断学的进步为综合医疗解决方案和个人化治疗提供了新途径，为放射性药物市场的持续成长奠定了基础。

主要市场统计
基准年[2023] 51.5亿美元
预测年份 [2024] 54.8亿美元
预测年份 [2030] 80亿美元
复合年增长率（%） 6.47%

治疗量：近距离放射治疗中同位素治疗的进展

放射性药物在现代医学的诊断和治疗方面都发挥着至关重要的作用。包括 PET 和 SPECT 放射性药物在内的诊断程序的程序量仍然很重要，因为它们在准确的疾病检测和监测方面具有重要的能力。 PET 扫描使用发射正子的放射性药物来提供代谢活动和血流等过程的高解析度功能影像。相较之下，SPECT 使用发射伽马射线的放射性药物来绘製生理功能图。在治疗过程中，α发射核素由于其高线性能量转移和短距离，可有效治疗微转移。 β发射核素具有更好的组织渗透性，使其适合治疗大量患病细胞。近距离放射治疗同位素疗法涉及将放射源直接植入肿瘤内或肿瘤附近，提供局部放射治疗，对周围健康组织的影响最小。

应用：增加放射性药物在治疗方法的使用

正子断层扫描 (PET) 透过详细显示心肌灌注和代谢，在心臟病学中发挥重要作用。 PET 可用于诊断各种心臟疾病，包括冠状动脉疾病、评估心肌活力以及监测治疗后的心肌健康状况。在神经病学中，PET 可提供有关脑血流、葡萄糖代谢和胺基酸摄取的宝贵见解。 PET 影像广泛用于评估神经退化性疾病，如帕金森氏症、癫痫和阿兹海默症。它在个人化神经病学患者照护中发挥着重要作用，因为它有助于早期诊断、追踪疾病进展和评估治疗性介入。 PET 影像由于能够灵敏地检测癌症并对其进行分期，因此在肿瘤学中极为重要。它对于定位肿瘤、了解代谢活动和评估治疗反应很有用。 PET 研究指南癌症治疗的临床决策，包括手术治疗计划、放射治疗和新化疗方案的评估，并为肿瘤干预提供了途径。

单光子放射电脑断层扫描通常用于心臟影像，以评估血流并检查心臟的泵血功能。检测缺血和梗塞区域并协助临床医生规划干预措施。 SPECT 影像在淋巴瘤患者的分期和后续观察中发挥重要作用。 SPECT可以找出淋巴结的精确位置并评估疾病的扩散情况，这对于调整治疗方法至关重要。在神经病学中，SPECT 可以分析脑血流并评估神经细胞的完整性。它用于评估中风、失智症和癫痫等疾病，并可用于确定功能障碍和治疗效果。 SPECT 对于甲状腺影像特别有用，可用于评估结节的存在和性质以及甲状腺功能亢进的情况。它提供有关甲状腺活动的功能信息，可用于甲状腺癌患者的管理，包括术后评估和转移检测。

放射性药物在骨转移的姑息治疗中发挥着至关重要的作用，其中转移性癌细胞已扩散到骨骼。向患者施用诸如锶89和钐153之类的放射性化合物，选择性地定位于骨转换增加的区域，并施用局部放射以减轻疼痛并提供阿片类镇痛剂，可以减少对药物的需求。放射性药物的使用已经改变了内分泌肿瘤（例如神经内分泌肿瘤（NET））的治疗。胜肽受体放射性核种疗法（PRRT）使用放射性标记的生长抑制素类似物（例如镏-177 dotatate），靶向癌细胞上的生长抑制素受体，并将细胞毒性辐射直接传递到肿瘤。淋巴瘤，特别非何杰金氏淋巴瘤(NHL) 的放射性药物治疗采用放射性标记的单株抗体，靶向恶性细胞表面的 CD20 抗原。与钇 90 结合的 ibritumomab tiuxetan (Zevalin) 等药物可以对癌细胞进行标靶放射治疗，对于对传统化疗有抵抗力或寻求不太积极的治疗方法。使用 iodine-131 进行放射性碘治疗是治疗甲状腺亢进和分化型甲状腺癌的既定治疗方法。这种有针对性的方法对于分化型甲状腺癌的术后​​管理至关重要，并且对于治疗和影像都很有用。

区域洞察

在核子医学和先进医疗基础设施进步的推动下，美洲放射性药物市场呈现强劲成长。美国由于研发投入大、报销政策优惠，对市场贡献大。由于意识的提高和医疗保健设施的改善，加拿大和拉丁美洲也在增长，儘管速度较慢。欧洲是欧洲、中东和非洲地区放射性药物市场的主要贡献者，慢性病发病率上升、人口老化以及医疗保健支出不断增加推动了放射性药物市场的普及。德国、法国和英国因其先进的医疗保健系统和政府支持措施而拥有强大的市场地位。中东和非洲是潜力开拓的新兴市场，其特点是医疗基础设施投资增加和诊断服务需求不断增长。然而，缺乏熟练的专业人员和各国经济分散可能对该地区的市场扩张构成挑战。亚太地区放射性药物市场正在经历快速成长，在不断发展的医疗保健领域拥有强大的研究基础，提供了巨大的成长机会。中国、日本、澳洲和韩国等国家处于这一成长的前沿。政府加强医疗保健现代化也支持了市场开拓。

FPNV定位矩阵

FPNV定位矩阵对于评估放射性药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对放射性药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估及资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行综合评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.放射性药物市场的市场规模与预测为何？

2.在放射性药物市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.放射性药物市场的技术趋势和法规结构是什么？

4.放射性药物市场主要厂商的市场占有率为何？

5.进入放射性药物市场的适当型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 目标疾病的发生率和盛行率增加
      • 基于α放射免疫疗法的标靶癌症治疗
      • 努力缩小Mo-99供需缺口
    • 抑制因素
      • 放射性药物的寿命会缩短。
    • 机会
      • 放射性药物在神经学应用上的采用
      • 增加诊断中心，特别是在新兴国家
    • 任务
      • 设备价格高且医院预算有限
  • 市场区隔分析
    • 手术数量：近距离放射治疗手术的持续进步
    • 应用：提高放射性药物在治疗过程中的使用率
  • 市场趋势分析
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化

第六章放射性药物市场：依类型

  • 核医学诊断
  • 核子医学治疗

第七章放射性药物市场：依手术数量分类

  • 诊断
  • 治疗

第八章放射性药物市场：依应用分类

  • 诊断用途
  • 治疗用途

第九章美洲放射性药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太放射性药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲放射性药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 百时美施贵宝透过收购 RaysBio 增加了一流的放射性药物平台
    • 新CRP开发用于疾病诊断的新型Technetium-99m放射性药物
    • 梅奥诊所支持的Start-Ups筹集了 5,600 万美元，瞄准放射性药物失败

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-4308E1C887A3

[191 Pages Report] The Radiopharmaceuticals Market size was estimated at USD 5.15 billion in 2023 and expected to reach USD 5.48 billion in 2024, at a CAGR 6.47% to reach USD 8.00 billion by 2030.

Radiopharmaceuticals are a unique category of medicinal formulations containing radioisotopes that are used in the field of nuclear medicine. These compounds, which are characterized by their ability to emit radiation, serve multiple purposes, including diagnosis, therapy, and research. Radiopharmaceuticals offer significant value in both the detection and treatment of disease, enhancing the capability for early diagnosis, monitoring of disease progression, and effectiveness of therapeutic interventions. Radiopharmaceutical compounds are experiencing significant adoption, driven by the rising prevalence of chronic diseases such as cancer and cardiovascular disorders that require advanced diagnostic techniques. Technological advancements in imaging technologies, such as PET and SPECT, are also catalyzing the radiopharmaceuticals market growth. Additionally, the increasing adoption of personalized medicine and targeted therapy approaches boosts the demand for radioisotopes in therapeutic applications. Despite considerable growth prospects, the radiopharmaceuticals market faces challenges, including stringent regulatory requirements that result in longer approval times for new radiopharmaceuticals. High costs for radiopharmaceutical development and production, as well as the requirement for specialized facilities and trained personnel, add to the list of challenges facing the industry. However, the increasing investment in research and development provides ample opportunities for innovation and expansion in the radiopharmaceutical market. Furthermore, ongoing advancements in theranostics, which combine diagnostic and therapeutic capabilities in a single agent, present new avenues for integrative healthcare solutions and personalized treatment, positioning the radiopharmaceuticals market for sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 5.15 billion
Estimated Year [2024] USD 5.48 billion
Forecast Year [2030] USD 8.00 billion
CAGR (%) 6.47%

Procedural Volume: Ongoing advancements in brachytherapy isotopes procedure

Radiopharmaceuticals play a pivotal role in modern medicine, both in diagnostics and therapy. The procedural volume for diagnostic procedures, including PET radiopharmaceuticals and SPECT radiopharmaceuticals, remains significant, owing to their critical function in accurate disease detection and monitoring. PET procedures utilize positron-emitting radiopharmaceuticals, providing high-resolution, functional imaging of processes such as metabolic activity or blood flow. In contrast, SPECT procedures involve gamma-emitting radiopharmaceuticals for mapping physiological functions. In therapeutic procedures, alpha emitters offer advantages owing to the high linear energy transfer and short range, making them effective in treating micrometastases. Beta emitter procedures are more recognized for treating larger volumes of diseased cells due to their broader tissue penetration. Brachytherapy isotope procedures involve implanting radioactive sources directly into or near a tumor, thus delivering localized radiation therapy with minimal impact on surrounding healthy tissue.

Application: Increasing utilization of radiopharmaceuticals in therapeutic procedures

Positron emission tomography (PET) has a crucial role in cardiology by enabling detailed visualization of myocardial perfusion and metabolism. It aids in diagnosing various heart conditions, including coronary artery disease, evaluating myocardial viability, and monitoring heart muscle health post-intervention. In neurology, PET provides valuable insights into cerebral blood flow, glucose metabolism, and amino acid uptake. PET imaging is widely utilized in the evaluation of neurodegenerative diseases, such as Parkinson's disease, epilepsy, and Alzheimer's disease. It aids in early diagnosis, tracking disease progression, and assessing therapeutic interventions, thereby playing a significant role in personalized neurological patient care. PET imaging is crucial in oncology due to its ability to detect and stage cancer with high sensitivity. It assists in pinpointing the location of tumors, understanding their metabolic activity, and evaluating responses to therapy. PET scans guide clinical decision-making in cancer treatment, including surgical planning, radiation therapy, and the assessment of new chemotherapy regimes, thereby offering a path to tailored oncologic interventions.

Single photon emission computed tomography is commonly used in cardiac imaging to evaluate blood flow and examine the pumping function of the heart. It detects areas of ischemia and infarction, assisting clinicians with intervention planning. SPECT imaging has a significant role in the staging and follow-up of lymphoma patients. It allows for the precise localization of lymph nodes and assessment of the disease spread, which is crucial for tailoring the treatment approach. In neurology, SPECT can analyze cerebral blood flow and assess neuronal integrity. It is used in the evaluation of disorders such as stroke, dementia, and seizure disorders, aiding in the determination of functional impairment and treatment efficacy. SPECT is particularly effective in thyroid imaging to evaluate the presence and nature of nodules and in cases of hyperthyroidism. It provides functional information about thyroid activity and assists in the management of thyroid cancer patients, including post-surgical assessment and detection of metastases.

Radiopharmaceuticals play a pivotal role in the palliative treatment of bone metastasis, where metastatic cancer cells have spread to bones. These radioactive compounds, such as Strontium-89 and Samarium-153, are administered to patients, where they selectively localize to areas of increased bone turnover, emitting local radiation that alleviates pain and can reduce the need for opioid analgesics, thereby improving the quality of life in patients with advanced cancers. The management of endocrine tumors, such as neuroendocrine tumors (NETs), has been transformed by the use of radiopharmaceuticals. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, such as Lutetium-177 dotatate, targets somatostatin receptors on tumor cells to deliver cytotoxic radiation directly to the tumor, minimizing the exposure to surrounding healthy tissue and offering an effective therapeutic option for inoperable or metastasized NETs. Radiopharmaceutical therapy for lymphoma, particularly non-Hodgkin lymphoma (NHL), incorporates radiolabeled monoclonal antibodies that target CD20 antigens on the surface of malignant cells. Agents such as Ibritumomab Tiuxetan (Zevalin) conjugated with Yttrium-90 deliver targeted radiotherapy to the cancerous cells, which can result in an effective response for patients with refractory to conventional chemotherapy or for those seeking a less aggressive treatment. Radioiodine therapy with Iodine-131 is a well-established treatment for hyperthyroidism and differentiated thyroid cancer. This targeted approach is crucial for differentiated thyroid carcinoma management post-surgery, aiding in both treatment and diagnostic imaging.

Regional Insights

The radiopharmaceutical market in the Americas has shown robust growth, driven by advancements in nuclear medicine and the advanced healthcare infrastructure. The United States contributes majorly to the market with its substantial investments in R&D and favorable reimbursement policies. Canada and Latin America are also experiencing growth, albeit at a slower pace, owing to increasing awareness and improving healthcare facilities. Europe is a significant contributor to the radiopharmaceutical market within the EMEA region, with adoption fuelled by the rising incidence of chronic illnesses, the aging population, and increased healthcare expenditure. Germany, France, and the UK have strong market positions due to their advanced healthcare systems and supportive government initiatives. The Middle East and Africa are emerging markets with untapped potential, characterized by increasing investment in healthcare infrastructure and a growing demand for diagnostic services. However, the scarcity of skilled professionals and economic variability across countries may challenge market expansion in this region. The Asia-Pacific radiopharmaceutical market is experiencing rapid growth, offering substantial opportunities due to its strong research base in evolving healthcare sectors. Countries such as China, Japan, Australia, and South Korea are at the forefront of this growth. The increasing government initiatives to modernize healthcare are propelling market development.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Radiopharmaceuticals Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Radiopharmaceuticals Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Radiopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Alliance Holdings Medical Limited, Bayer AG, Bracco Group, BWX Technologies. Inc., BWXT Medical Ltd., Cardinal Health, Inc., Clarity Pharmaceuticals, Curium Pharma, Eckert & Ziegler Group, Eczacibasi-Monrol Nuclear Products Co., Fusion Pharmaceuticals Inc., GE HealthCare Technologies, Inc., Global Medical Solutions, Institute of Isotopes Co. Ltd., International Isotopes, Inc., IsoTherapeutics Group, LLC, Isotopia Molecular Imaging Ltd., Jubilant Pharma Holdings Inc., Lantheus Medical Imaging, Inc., Mallinckrodt PLC, Medi-Radiopharma, Northstar Medical Technologies LLC, Novartis AG, NTP Radioisotopes SOC Ltd., SHINE Medical Technologies, Siemens Healthineers AG, Sinotau Pharmaceutical Group, and State Atomic Energy Corporation Rosatom.

Market Segmentation & Coverage

This research report categorizes the Radiopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Diagnostic Nuclear Medicine
      • Pet Radiopharmaceuticals
        • F-18
        • Ru-82
      • Spect Radiopharmaceuticals
        • Ga-67
        • I-123
        • Tc-99m
        • Tl-201
    • Therapeutic Nuclear Medicine
      • Alpha Emitters
      • Beta Emitters
        • I-131
        • Lu-177
        • Re-186
        • Sm-153
        • Y-90
      • Brachytherapy Isotopes
        • Cs-131
        • I-125
        • Ir-192
        • Pd-103
  • Procedural Volume
    • Diagnostic Procedures
      • Pet Radiopharmaceutical Procedure
      • Spect Radiopharmaceuticals Procedure
    • Therapeutic Procedures
      • Alpha Emitter Procedure
      • Beta Emitters Procedure
      • Brachytherapy Isotopes Procedure
  • Application
    • Diagnostic Applications
      • Pet Applications
        • Cardiology Indication
        • Neurology Indication
        • Oncology Indication
      • Spect Applications
        • Cardiology
        • Lymphoma
        • Neurology
        • Thyroid
    • Therapeutic Applications
      • Bone Metastasis
      • Endocrine Tumors
      • Lymphoma Therapeutic
      • Thyroid Therapeutic
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Radiopharmaceuticals Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Radiopharmaceuticals Market?

3. What are the technology trends and regulatory frameworks in the Radiopharmaceuticals Market?

4. What is the market share of the leading vendors in the Radiopharmaceuticals Market?

5. Which modes and strategic moves are suitable for entering the Radiopharmaceuticals Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Incidence and Prevalence of Target Conditions
      • 5.1.1.2. Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
      • 5.1.1.3. Initiatives To Reduce The Demand-Supply Gap of mo-99
    • 5.1.2. Restraints
      • 5.1.2.1. Shorter Life of Radiopharmaceuticals
    • 5.1.3. Opportunities
      • 5.1.3.1. Adoption of Radiopharmaceuticals in Neurological Applications
      • 5.1.3.2. Rising Number of Diagnostic Centers Especially in Developing Countries
    • 5.1.4. Challenges
      • 5.1.4.1. High Equipment Prices and Limited Hospital Budget
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Procedural Volume: Ongoing advancements in brachytherapy isotopes procedure
    • 5.2.2. Application: Increasing utilization of radiopharmaceuticals in therapeutic procedures
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Radiopharmaceuticals Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnostic Nuclear Medicine
  • 6.3. Therapeutic Nuclear Medicine

7. Radiopharmaceuticals Market, by Procedural Volume

  • 7.1. Introduction
  • 7.2. Diagnostic Procedures
  • 7.3. Therapeutic Procedures

8. Radiopharmaceuticals Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostic Applications
  • 8.3. Therapeutic Applications

9. Americas Radiopharmaceuticals Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Radiopharmaceuticals Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Radiopharmaceuticals Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
    • 12.3.2. New CRP to Develop new Technetium-99m Radiopharmaceuticals for Disease Diagnosis
    • 12.3.3. With USD 56 Million, a Mayo Clinic-backed Startup takes aim at Radiopharmaceutical Roadblocks

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. RADIOPHARMACEUTICALS MARKET RESEARCH PROCESS
  • FIGURE 2. RADIOPHARMACEUTICALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. RADIOPHARMACEUTICALS MARKET DYNAMICS
  • FIGURE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RADIOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RU-82, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RU-82, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GA-67, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GA-67, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-123, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-123, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TL-201, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY TL-201, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-131, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-131, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RE-186, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RE-186, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SM-153, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SM-153, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CS-131, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CS-131, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-125, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY I-125, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IR-192, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY IR-192, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PD-103, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PD-103, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICAL PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICAL PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 76. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 77. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 78. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 79. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTER PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 80. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTER PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 81. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 82. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 83. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES PROCEDURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 84. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES PROCEDURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 85. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 88. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 89. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 90. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 91. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 92. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 93. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 94. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 95. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY INDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 96. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY INDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 97. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY INDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 98. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY INDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 99. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY INDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 100. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY INDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 101. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 102. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 103. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 104. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 105. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 106. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 107. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 108. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 109. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 110. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 111. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 112. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 113. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 114. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 115. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 116. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 117. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BONE METASTASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 118. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY BONE METASTASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 119. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINE TUMORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 120. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ENDOCRINE TUMORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 121. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA THERAPEUTIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 122. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY LYMPHOMA THERAPEUTIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 123. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID THERAPEUTIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 124. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THYROID THERAPEUTIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 125. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 128. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 129. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 130. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 131. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 132. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 133. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 134. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 135. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 136. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 137. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 138. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 139. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 140. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 141. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 142. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 143. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 144. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 145. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 148. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 149. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 150. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 151. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 152. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 153. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 154. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 155. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. AMERICAS RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 160. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 161. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 162. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 163. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 164. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 165. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 166. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 167. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 168. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 169. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 170. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 171. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 172. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 173. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 174. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 175. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 176. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 177. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 180. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 181. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 182. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 183. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 184. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 185. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 186. ARGENTINA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 187. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 190. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 191. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 192. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 193. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 194. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 195. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 196. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 197. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 198. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 199. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 200. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 201. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 202. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 203. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 204. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 205. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 206. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 207. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 210. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 211. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 212. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 213. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 214. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 215. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 216. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 217. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 220. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 221. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 222. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 223. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 224. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 225. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 226. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 227. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 228. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 229. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 230. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 231. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 232. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 233. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 234. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 235. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 236. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 237. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 240. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 241. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 242. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 243. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 244. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 245. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 246. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 247. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 250. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 251. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 252. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 253. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 254. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 255. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 256. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 257. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 258. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 259. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 260. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 261. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 262. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 263. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 264. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 265. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 266. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 267. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 270. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 271. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 272. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 273. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 274. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 275. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 276. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 287. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2018-2023 (USD MILLION)
  • TABLE 288. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTERS, 2024-2030 (USD MILLION)
  • TABLE 289. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2023 (USD MILLION)
  • TABLE 290. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2024-2030 (USD MILLION)
  • TABLE 291. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2018-2023 (USD MILLION)
  • TABLE 292. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PROCEDURAL VOLUME, 2024-2030 (USD MILLION)
  • TABLE 293. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 294. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 295. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2018-2023 (USD MILLION)
  • TABLE 296. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC PROCEDURES, 2024-2030 (USD MILLION)
  • TABLE 297. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 300. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 301. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 302. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PET APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 303. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 304. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 305. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 306. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 307. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 308. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2023 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2024-2030 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2023 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2024-2030 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC